The aim of the study was to examine the hypotensive efficacy and tolerance of bisoprolol in elderly patients. Sixty patients (40 Ͻ65 years and 20 Ͼ65 years) with mild-to-moderate essential hypertension (diastolic blood pressure (DBP) between 95 and 109 mm Hg) were included in the study. After a 2-week run-in period on placebo, patients began bisoprolol therapy (5 mg/d) for 12 weeks. After 4 weeks the dose was increased to 10 mg/d in those with a DBP у95 mm Hg. Additionally, in 10 patients over 65 years old, 24-h ambulatory BP monitoring (ABPM) was performed, after placebo and
Introduction
For several years it has been thought that beta-adrenergic blockers are less effective in elderly patients. However, studies on the effectiveness of beta-blockers in the elderly have yielded conflicting results. At present it is postulated that new beta adrenoceptor antagonists with high ␤1 selectivity are an alternative to other drugs in elderly patients with mild-tomoderate essential hypertension. Owing to the advantageous properties these drugs are well tolerated in the elderly. In the present study we compared the anti-hypertensive effect and tolerance of bisoprolol in two population groups (young Ͻ65 years, and elderly Ͼ65 years). Bisoprolol is a new high ␤ 1 -selective adrenoceptor antagonist without intrinsic sympathomimetic activity (ISA), and with a plasma elimination half-life of 10-12 h permitting treatment with once daily dose.
Materials and methods
The study was performed in 60 patients with mildto-moderate hypertension (diastolic blood pressure (DBP) 95-109 mm Hg; systolic BP (SBP) 160-180 mm Hg). The patients were divided into two groups: group 1 included 40 patients Ͻ65 years (mean age 49 ± 5.4; 19 men, 21 women; and group 2 was composed of 20 patients Ͼ65 years (mean age 67.6 ± 3.8; 9 men, 11 women). All patients received bisoprolol (5 mg/d) and after 4 weeks, if DBP was у95 mm Hg, the dosage was doubled. The total active treatment phase lasted 12 weeks. BP was measured in all patients with a standard mercury sphygmomanCorrespondence: Marlena Broncel,Department of Clinical Pharmacology, MMA, Bieganski Hospital, 1/5 Kniaziewicza Street, 91-347 Lodz, Poland after bisoprolol (5 mg) administration. The hypotensive efficacy of bisoprolol in the elderly and younger patients was similar. Before and after treatment the mean difference of systolic BP (SBP) was 19.6 ± 12.5 mm Hg and DBP 9.6 ± 6.2 mm Hg in the younger patients and 16.1 ± 13.6 mm Hg and 9.5 ± 6.0 mm Hg in the elderly patients. Bisoprolol produced a similar reduction in heart rate (23.1% vs 17.1%) in the estimated groups. The tolerance of bisoprolol was good in both groups. There were no significant differences in adverse drug reactions between the groups.
ometer in the sitting position, after a 10-min rest, three times. BP was measured on the first day of the placebo phase and three times during the active treatment. Additionally at each visit the heart rate and side effects were assessed. Furthermore in 10 patients over 65 years, 24-h ambulatory BP monitoring (ABPM by Oxford Medilog system) was performed, after placebo and after bisoprolol (5 mg) administration.
Results
Bisoprolol produced a similar reduction in BP in both the elderly and younger patients. After the treatment the mean difference of SBP and DBP was 19.6/9.6 mm Hg in patients Ͻ65 and 16.1/9.5 in patients Ͼ65 years. We observed a similar reduction in heart rate in both groups (23.1% vs 17.1%, Table 1 ). The reduction in SBP and DBP in the elderly patients treated with bisoprolol (5 mg) was maintained throughout the 24-h dosing interval (Figure 1 ). There was no significant difference in adverse drug reactions and quality of life. Only two patients after 1 month of active treatment were withdrawn from the study because of bradycardia. Furthermore the deterioration of heart failure and of peripheral circulation in the elderly was not observed.
Discussion
The use of drugs of all types in the elderly is more difficult than in younger patients, for the aging process is associated with altered pharmacokinetics and drug responses. 1 The use of beta-blockers in the treatment of hypertension in elderly patients is not clear. It has been claimed that beta-blockers are less effective than diuretics. 2 However, Neutel et al 3 found in their study that two beta-blockers (atenolol, bisoprolol) have clearly different anti-hypertensive effects in patients over 65 years of age. Bisoprolol produced a greater reduction in BP than atenolol. Owing to the long time duration bisoprolol in a single dose per day is sufficient to control BP during 24 h and prevents the rise of BP in the early morning. 3 Hypertension in the elderly patients is characterised by a blunted baroreflex and ␤ 1 -adrenoceptormediated reponses, decreased vascular compliance and increased peripheral vascular resistance. 1 One possible explanation for the enhanced efficacy of bisoprolol in the elderly may be that it is more lipid soluble than atenolol. 4 Sympathetic nervous system activity may be critical in patients over 65 years in whom reduced arterial compliance may contribute to hypertension and central drug effects may be important in regulating BP. 4 Owing to the advantageous pharmacodynamic and pharmacokinetic properties bisoprolol is better tolerated than other beta-blocking agents in the elderly. 5 The implication of our study is that bisoprolol is very efficient and safe in the treatment of hypertension in patients over 65 years of age.
